Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | GIMEMA AML1310: 6-year follow-up results

Raffaele Palmieri, MD, University of Rome “Tor Vergata”, Rome, Italy, shares the results from the six-year follow-up of the GIMEMA AML1310 trial (NCT01452646) evaluating risk-adapted, measurable residual disease (MRD)-adapted therapy in young adults with newly diagnosed intermediate-risk acute myeloid leukemia (AML). In this study, patients who were MRD-positive after consolidation underwent allogeneic transplantation whilst patients who were MRD-negative underwent autologous transplantation The study reported similar outcomes between patients who underwent autologous and allogeneic transplantation and confirmed that integrating MRD and dynamic risk assessment after consolidation therapy allows making better treatment decisions. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.